ModerateDirect oral anticoagulants (factor Xa inhibitors)×Selective serotonin reuptake inhibitors
Updated · Methodology
Mechanism
Edoxaban selectively, directly and reversibly inhibits coagulation factor Xa (edoxaban summary of product characteristics, SmPC, European Medicines Agency, EMA). Fluoxetine carries a risk of increased bleeding when combined with drugs that affect haemostasis, including oral anticoagulants of any mechanism (fluoxetine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The edoxaban SmPC warns that, as with other anticoagulants, selective serotonin reuptake inhibitors (SSRIs) may raise the risk of bleeding through their reported effect on platelets (EMA). Fluoxetine and its active metabolite norfluoxetine are eliminated slowly and remain in the body for 5–6 weeks after the drug is stopped (fluoxetine SmPC, AEMPS). No clinical or pharmacokinetic data are available for edoxaban with these antidepressants (European Heart Rhythm Association practical guide, EHRA 2021).
Symptoms
The risk of bleeding rises. Bleeding can occur at any site and may be severe or even fatal (edoxaban summary of product characteristics, SmPC, European Medicines Agency, EMA). The most frequently reported adverse reactions with edoxaban are nosebleeds, blood in the urine and anaemia (EMA). Bleeding complications may present as weakness, pallor, dizziness, headache, unexplained swelling, shortness of breath or shock with no apparent cause (EMA). Bleeding into the skin, such as bruising and purpura, occurs with selective serotonin reuptake inhibitors (SSRIs). With fluoxetine, bruising is uncommon, and gynaecological, gastrointestinal and other skin or mucosal bleeding has been reported rarely (fluoxetine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS).
Management
The combination is not contraindicated, but, as with other anticoagulants, use edoxaban with caution in patients at increased risk of bleeding (edoxaban summary of product characteristics, SmPC, European Medicines Agency, EMA). Use fluoxetine with caution, especially together with oral anticoagulants and in patients with a history of bleeding disorders (fluoxetine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). For patients taking an oral anticoagulant, the fluoxetine SmPC asks for more frequent clinical monitoring of the INR, the international normalised ratio (AEMPS). With edoxaban, however, the INR and other standard coagulation tests change little and vary widely, so they are not useful for monitoring its effect (edoxaban SmPC, EMA). When assessing interactions, take into account the long half-lives of fluoxetine and norfluoxetine. Fluoxetine remains in the body for 5–6 weeks after it is stopped (fluoxetine SmPC, AEMPS). The European Heart Rhythm Association (EHRA) states that caution is required, especially with polypharmacy or with two or more bleeding risk factors. Examples include antiplatelet drugs, non-steroidal anti-inflammatory drugs, systemic steroids, previous bleeding or a predisposition to it (anaemia, thrombocytopenia), severe frailty and risk of falls (EHRA 2021). Promptly evaluate any signs or symptoms of blood loss (US edoxaban prescribing information, US Food and Drug Administration, FDA). Haemoglobin and haematocrit may help detect hidden bleeding. If haemoglobin or blood pressure falls without explanation, look for a bleeding site, and stop edoxaban if severe bleeding occurs (edoxaban SmPC, EMA).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Fluoxetina, Fluoxetina Cinfa 20 mg (nº registro 63499) (2026)– AEMPS, CIMA, nº registro 63499 (Fluoxetina Cinfa 20 mg cápsulas duras EFG), revisión 10/2026, secciones 4.3, 4.4 y 4.5
- EHRA: 2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation (2021)– Steffel J, Collins R, Antz M, et al. 2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace. 2021;23(10):1612–1676, Tables 5–8 and Figure 6
- FDA: SAVAYSA (edoxaban) tablets, prescribing information (2023)– FDA, SAVAYSA (edoxaban tosylate) prescribing information, Daiichi Sankyo, NDA 206316, revised 10/2023 (DailyMed)
- EMA: Ficha técnica: Edoxabán, Lixiana 60 mg (EU/1/15/993), secciones 4.4 y 4.5 (2025)– EMA, ficha técnica de Lixiana 60 mg comprimidos recubiertos con película (Daiichi Sankyo Europe), EU/1/15/993, texto en CIMA nº registro 115993018, información del producto de la EMA actualizada 27/08/2025, secciones 4.2, 4.3, 4.4, 4.5, 4.8, 4.9 y 5.2